Long-acting β₂ agonists: Pfizer’s development candidate?

Abstract

Two applications claim novel long-acting β₂ agonists. The first covers a range of structures with a generic claim, highlighting a modular approach to the identification of such agents, coupling various β₂ agonist pharmacophoric groups via a common phenyethylamine linker to lipophilic tail groups. The second application claims a single compound, the tartrate salt of a previously disclosed compound from this effort, suggesting that the claimed compound is a clinical candidate.

Keywords::

• β adrenoceptor
• β₂ agonist
• asthma
• COPD

Patent details

• Title Compounds For The Treatment Of Diseases

• Assignee Pfizer Ltd

• Inventors Glossop PA, Lane CA, Lunn G, Price DA

• Priority date 12/11/04

• Filing date 31/10/05

• Publication date 18/05/06

• Publication no. WO2006051373

• Title L-tartrate Salt of N-1-adamanthyl- 2-{3-[(2r)-2-({(2R)-2-hydroxy-2-[4-hydroxy-3- (hydroxymethyl)phenyl]ethyl}amino)propyl] phenyl}acet Amide

• Assignee Pfizer Ltd

• Inventors James K, Taylor SC

• Priority date 12/11/04

• Filing date 31/10/05

• Publication date 18/05/06

• Publication no. WO2006051375

Notes